H. Lundbeck A/S- (NASDAQ:HLUYY) has been assigned an average broker rating score of 3.00 (Hold) from the one brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating.

Zacks has also given H. Lundbeck A/S- an industry rank of 120 out of 265 based on the ratings given to its competitors.

HLUYY has been the subject of a number of recent analyst reports. Deutsche Bank AG cut H. Lundbeck A/S- from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Zacks Investment Research cut H. Lundbeck A/S- from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. Finally, Jefferies Group LLC cut H. Lundbeck A/S- from a “buy” rating to a “hold” rating in a research report on Tuesday, April 11th.

H. Lundbeck A/S- (NASDAQ HLUYY) traded down 1.183% on Tuesday, hitting $60.659. The stock had a trading volume of 300 shares. The company has a 50-day moving average price of $57.45 and a 200-day moving average price of $49.19. The stock has a market capitalization of $11.97 billion and a price-to-earnings ratio of 47.464. H. Lundbeck A/S- has a 1-year low of $31.00 and a 1-year high of $61.72.

WARNING: “H. Lundbeck A/S- (NASDAQ:HLUYY) Receives Average Rating of “Hold” from Analysts” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/08/h-lundbeck-as-nasdaqhluyy-receives-average-rating-of-hold-from-analysts.html.

About H. Lundbeck A/S-

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and schizophrenia.

Get a free copy of the Zacks research report on H. Lundbeck A/S- (HLUYY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for H. Lundbeck A/S- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S- and related companies with MarketBeat.com's FREE daily email newsletter.